Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin.2000;50:7-33.
Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin.1999;49:8-31.
Ries LA, Kosary CL, Hankey BF.
et al. SEER Cancer Statistic Review, 1973-1995. Bethesda, Md: National Cancer Institute; 1998.
Sgroi DC, Teng S, Robinson G.
et al. In vivo gene expression profile analysis of human breast cancer progression. Cancer Res.1999;59:5656-5661.
Villaret DB, Wang T, Dillon D.
et al. Identification of genes overexpressed in head and neck squamous cell
carcinoma using a combination of complementary DNA subtraction and microarray
Wong KK, Cheng RS, Mok SC. Identification of differentially expressed genes from ovarian cancer
cells by MICROMAX cDNA microarray system. Biotechniques.2001;30:670-675.
Bull JH, Ellison G, Patel A.
et al. Identification of potential diagnostic markers of prostate cancer and
prostatic intraepithelial neoplasia using cDNA microarray. Br J Cancer.2001;84:1512-1519.
Kononen J, Bubendorf L, Kallioniemi A.
et al. Tissue microarrays for high-throughput molecular profiling of tumor
specimens. Nat Med.1998;4:844-847.
Dhanasekaran SM, Barrette TR, Ghosh D.
et al. Delineation of prognostic biomarkers in prostate cancer. Nature.2001;412:822-826.
Tsao SW, Mok SC, Fey EG.
et al. Characterization of human ovarian surface epithelial cells immortalized
by human papilloma viral oncogenes (HPV-E6E7 ORFs). Exp Cell Res.1995;218:499-507.
Cramer DW, Kuper H, Harlow BL, Titus-Ernstoff L. Carotenoids, antioxidants and ovarian cancer risk in pre- and postmenopausal
women. Int J Cancer.2001;94:128-134.
Cramer DW, Greenberg ER, Titus-Ernstoff L.
et al. A case-control study of galactose consumption and metabolism in relation
to ovarian cancer. Cancer Epidemiol Biomarkers Prev.2000;9:95-101.
Mok SC, Chao J, Skates S.
et al. Prostasin, a potential serum marker for ovarian cancer. J Natl Cancer Inst.2001;93:1458-1464.
Heid CA, Stevens J, Livak L, Williams IM. Real time quantitative PCR. Genome Res.1996;6:986-994.
Absolute and relative quantitation. In: GeneAmp 5700 User's Manual. Foster City,
Calif: PE Applied Biosystems; 1998:A9-A11.
Chan WY, Cheung KK, Schorge JO.
et al. Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human
epithelial ovarian cancers. Am J Pathol.2000;156:409-417.
Xu Y, Shen Z, Wiper DW.
et al. Lysophosphatidic acid as a potential biomarker for ovarian and other
gynecologic cancers. JAMA.1998;280:719-723.
Tuxen MK, Soletormos G, Petersen PH.
et al. Assessment of biological variation and analytical imprecision of CA
125, CEA, and TPA in relation to monitoring of ovarian cancer. Gynecol Oncol.1999;74:12-22.
Sandmaier BM, Oparin DV, Holmberg LA.
et al. Evidence of a cellular immune response against sialyl-Tn in breast
and ovarian cancer patients after high-dose chemotherapy, stem cell rescue,
and immunization with Theratope STn-KLH cancer vaccine. J Immunother.1999;22:54-66.
Luo LY, Katsaros D, Scorilas A.
et al. Prognostic value of human kallikrein 10 expression in epithelial ovarian
carcinoma. Clin Cancer Res.2001;7:2372-2379.
Negishi Y, Iwabuchi H, Sakunaga H.
et al. Serum and tissue measurements of CA72-4 in ovarian cancer patients. Gynecol Oncol.1993;48:148-154.
Hogdall CK, Mogensen O, Tabor A.
et al. The role of serum tetranectin, CA 125, and a combined index as tumor
markers in women with pelvic tumors. Gynecol Oncol.1995;56:22-28.
Jacobs IJ, Skates SJ, MacDonald N.
et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet.1999;353:1207-1210.
Chackalaparampil I, Banerjee D, Poirier Y, Mukherjee BB. Altered processing of a major secreted phosphoprotein correlates with
tumorigenicity in Rous sarcoma virus-transformed mammalian cells. J Virol.1985;53:841-850.
Prince CW, Oosawa T, Butler WT.
et al. Isolation, characterization, and biosynthesis of a phosphorylated glycoprotein
from rat bone. J Biol Chem.1987;262:2900-2907.
Smith JH, Denhardt DT. Molecular cloning of a tumor promoter-inducible mRNA found in JB6 mouse
epidermal cells: induction is stable at high, but not at low, cell densities. J Cell Biochem.1987;34:13-22.
Patarca R, Freeman GJ, Singh RP.
et al. Structural and functional studies of the early T lymphocyte activation
1 (Eta-1) gene. J Exp Med.1989;170:145-161.
Senger DR, Perruzzi CA, Papadopoulos A. Elevated expression of secreted phosphoprotein I (osteopontin, 2ar)
as a consequence of neoplastic transformation. Anticancer Res.1989;9:1291-1299.
Giachelli C, Bae N, Lombardi D.
et al. Molecular cloning and characterization of 2B7, a rat mRNA which distinguishes
smooth muscle cell phenotypes in vitro and is identical to osteopontin (secreted
phosphoprotein I, 2aR). Biochem Biophys Res Commun.1991;177:867-873.
Liaw L, Skinner MP, Raines EW.
et al. The adhesive and migratory effects of osteopontin are mediated via
distinct cell surface integrins. J Clin Invest.1995;95:713-724.
Weber GF, Ashkar S, Glimcher MJ, Cantor H. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science.1996;271:509-512.
Giachelli CM, Lombardi D, Johnson RJ.
et al. Evidence for a role of osteopontin in macrophage infiltration in response
to pathological stimuli in vivo. Am J Pathol.1998;152:353-358.
Crawford HC, Matrisian LM, Liaw L. Distinct roles of osteopontin in host defense activity and tumor survival
during squamous cell carcinoma progression in vivo. Cancer Res.1998;58:5206-5215.
Nau GJ, Guilfoile P, Chupp GL.
et al. A chemoattractant cytokine associated with granulomas in tuberculosis
and silicosis. Proc Natl Acad Sci U S A.1997;94:6414-6419.
Singh RP, Patarca R, Schwartz J.
et al. Definition of a specific interaction between the early T lymphocyte
activation 1 (Eta-1) protein and murine macrophages
in vitro and its effect upon macrophages in vivo. J Exp Med.1990;171:1931-1942.
Hwang SM, Lopez CA, Heck DE.
et al. Osteopontin inhibits induction of nitric oxide synthase gene expression
by inflammatory mediators in mouse kidney epithelial cells. J Biol Chem.1994;269:711-715.
McKee MD, Nanci A. Secretion of osteopontin by macrophages and its accumulation at tissue
surfaces during wound healing in mineralized tissues. Anat Rec.1996;245:394-409.
Shijubo N, Uede T, Kon S.
et al. Vascular endothelial growth factor and osteopontin in stage I lung
adenocarcinoma. Am J Respir Crit Care Med.1999;160:1269-1273.
Tunio GM, Hirota S, Nomura S, Kitamura Y. Possible relation of osteopontin to development of psammoma bodies
in human papillary thyroid cancer. Arch Pathol Lab Med.1998;122:1087-1090.
Maki M, Hirota S, Kaneko Y, Morohoshi T. Expression of osteopontin messenger RNA by macrophages in ovarian serous
papillary cystadenocarcinoma. Pathol Int.2000;50:531-535.
Tiniakos DG, Yu H, Liapis H. Osteopontin expression in ovarian carcinomas and tumors of low malignant
potential (LMP). Hum Pathol.1998;29:1250-1254.
Thalmann GN, Sikes RA, Devoll RE.
et al. Osteopontin: possible role in prostate cancer progression. Clin Cancer Res.1999;5:2271-2277.
Kim YW, Park YK, Lee J.
et al. Expression of osteopontin and osteonectin in breast cancer. J Korean Med Sci.1998;13:652-657.
Tuck AB, O'Malley FP, Singhal H.
et al. Osteopontin expression in a group of lymph node negative breast cancer
patients. Int J Cancer.1998;79:502-508.
Ue T, Yokozaki H, Kitadai Y.
et al. Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer.1998;79:127-132.
Giachelli CM, Liaw L, Murry CE.
et al. Osteopontin expression in cardiovascular diseases. Ann N Y Acad Sci.1995;760:109-126.
Casson AG, Wilson SM, McCart JA.
et al. ras mutation and expression of the ras-regulated genes osteopontin and cathepsin L in human esophageal
cancer. Int J Cancer.1997;72:739-745.
Zhang J, Takahashi K, Takahashi F.
et al. Differential osteopontin expression in lung cancer. Cancer Lett.2001;171:215-222.